+Compare
ZOM
Stock ticker: ASE
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
163.65M

ZOM Price Prediction, Zomedica Corp AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for ZOM with price predictions
08:00 PM EDT Sep 21, 2023

ZOM in -6.16% downward trend, declining for three consecutive days on September 21, 2023

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ZOM declined for three days, in of 351 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 07, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on ZOM as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Aroon Indicator for ZOM entered a downward trend on September 22, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ZOM's RSI Indicator exited the oversold zone, of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 64 cases where ZOM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ZOM advanced for three days, in of 227 cases, the price rose further within the following month. The odds of a continued upward trend are .

ZOM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.631) is normal, around the industry mean (85.810). P/E Ratio (0.000) is within average values for comparable stocks, (58.521). ZOM's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (3.385). ZOM has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.027). P/S Ratio (7.294) is also within normal values, averaging (61.746).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ZOM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZOM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Intra-Cellular Therapies (NASDAQ:ITCI), Bausch Health Companies (NYSE:BHC), Tilray Brands (NASDAQ:TLRY), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 2.59B. The market cap for tickers in the group ranges from 246 to 81.33B. ZTS holds the highest valuation in this group at 81.33B. The lowest valued company is PEMTF at 246.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was 3%. For the same Industry, the average monthly price growth was 19%, and the average quarterly price growth was 10%. CHHE experienced the highest price growth at 1,900%, while INNPF experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was -55%. For the same stocks of the Industry, the average monthly volume growth was 85% and the average quarterly volume growth was 72%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 71
Price Growth Rating: 58
SMR Rating: 85
Profit Risk Rating: 92
Seasonality Score: -11 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company that develops medication for animals

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
100 Phoenix Drive
Phone
+1 734 369-2555
Employees
85
Web
https://www.zomedica.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ADTDX21.54-0.02
-0.09%
Allspring Dynamic Target 2065 Admin
BOSOX15.56-0.02
-0.13%
Boston Trust Walden Small Cap
DNLDX50.77-0.09
-0.18%
BNY Mellon Active MidCap A
JCNAX24.70-0.11
-0.44%
Janus Henderson Contrarian A
CLIQX17.18-0.11
-0.64%
Clifford Capital Partners Super Instl

ZOM and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZOM has been loosely correlated with SNDL. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ZOM jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZOM
1D Price
Change %
ZOM100%
+0.54%
SNDL - ZOM
38%
Loosely correlated
+1.58%
DRRX - ZOM
34%
Loosely correlated
-1.85%
EBS - ZOM
29%
Poorly correlated
-5.23%
DCPH - ZOM
27%
Poorly correlated
-2.79%
VTRS - ZOM
27%
Poorly correlated
-0.52%
More